Aptose Biosciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Bernd R. Seizinger, former director of Aptose Biosciences Inc., reported transactions involving common shares and stock options on June 30, 2026, related to a business arrangement agreement.
Warren Whitehead reports changes in beneficial ownership of Aptose Biosciences Inc. common shares and stock options, reflecting a business arrangement agreement.
Former Aptose Biosciences director Mark D. Vincent has disposed of common shares and exercised stock options as part of a business arrangement agreement leading to the company's acquisition.
William G. Rice, CEO of Aptose Biosciences, reported changes in his beneficial ownership of company securities, including the disposition of common shares and various derivative securities.
Erich Platzer, former director of Aptose Biosciences Inc., has reported transactions involving common shares and stock options.
Fletcher Payne, former SVP and CFO of Aptose Biosciences, reported the disposition of common shares and stock options following the company's acquisition by Hammi Pharmaceuticals.
Denis R. Burger, former director of Aptose Biosciences Inc., reported transactions involving common shares and stock options on June 30, 2026.
Rafael Bejar, former SVP & Chief Medical Officer of Aptose Biosciences Inc., has reported changes in his beneficial ownership of company securities.
Aptose Biosciences' CEO, William G. Rice, acquired 100,000 common shares and 50,000 warrants as part of a unit offering.
Philippe Ledru, a former officer of Aptose Biosciences Inc., filed a Form 4 indicating changes in beneficial ownership of the company's securities.